UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2024
OR
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from to
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or
organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (646 ) 854-6565
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class:
|
Trading
Symbol:
|
Name of Each Exchange on
Which Registered:
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
|
☒
|
Smaller reporting company
|
|
|
Emerging growth company
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐
As of May 17, 2024, there were 13,070,291 Class A ordinary shares, par value $0.0001 per share (made up of 6,257,791 redeemable Class A ordinary shares and 6,812,500
non-redeemable Class A ordinary shares) and 1,812,500 Class B ordinary shares, par value $0.0001 per share, issued and outstanding.
Enphys Acquisition Corp.
Quarterly Report on Form 10-Q
|
PART I. FINANCIAL INFORMATION
|
Page No.
|
|
|
Item 1.
|
1
|
|
|
1
|
||
|
2
|
||
|
3
|
||
|
4
|
||
|
5
|
||
|
Item 2.
|
20
|
|
|
Item 3.
|
24
|
|
|
Item 4.
|
25
|
|
|
26
|
||
|
Item 1.
|
26
|
|
|
Item 1A.
|
26
|
|
|
Item 2.
|
26
|
|
|
Item 3.
|
26
|
|
|
Item 4.
|
26
|
|
|
Item 5.
|
27
|
|
|
Item 6.
|
27
|
|
|
28
|
||
ENPHYS ACQUISITION CORP.
| March 31, 2024
|
December 31, 2023
|
|||||||
|
|
(unaudited)
|
|||||||
|
ASSETS
|
||||||||
| Current Assets: |
||||||||
|
Cash
|
$
|
|
$ | |||||
| Prepaid expenses |
||||||||
| Total Current Assets |
||||||||
|
Cash held in Trust Account
|
||||||||
|
Total Assets
|
$
|
|
$ | |||||
|
|
||||||||
|
LIABILITIES, REDEEMABLE CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT
|
||||||||
|
Current Liabilities:
|
||||||||
|
Accounts payable
|
$
|
|
$ | |||||
| Accrued expenses |
||||||||
| Accrued offering costs |
||||||||
| Sponsor extension note |
||||||||
| Notes payable – related parties |
||||||||
|
Total Current Liabilities
|
|
|||||||
| Derivative warrant liabilities | ||||||||
| Deferred underwriting fees | ||||||||
|
Total Liabilities
|
||||||||
|
COMMITMENTS AND CONTINGENCIES
|
||||||||
| Redeemable Class A Ordinary Shares subject to Possible Redemption: | ||||||||
|
Class A ordinary shares, $
|
||||||||
|
|
||||||||
|
Shareholders’ deficit:
|
||||||||
|
Preferred shares, $
|
|
|||||||
|
Class A ordinary shares, $
|
|
|||||||
|
Class B ordinary shares, $
|
||||||||
|
Additional paid-in capital
|
|
|||||||
|
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
|
Total Shareholders’ Deficit
|
(
|
)
|
( |
) | ||||
|
Total Liabilities, Redeemable Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
|
$
|
|
||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
ENPHYS ACQUISITION CORP.
(unaudited)
|
For the Three Months Ended
March 31,
|
||||||||
| 2024 |
2023 | |||||||
|
EXPENSES
|
||||||||
|
Administration fee - related party
|
$
|
|
$
|
|
||||
|
General and administrative expenses
|
|
|
||||||
|
TOTAL EXPENSES
|
|
|
||||||
|
OTHER INCOME (EXPENSE)
|
||||||||
|
Income earned on cash and marketable securities held in Trust Account
|
|
|
||||||
|
Change in fair value of derivative warrant liabilities
|
(
|
)
|
(
|
)
|
||||
|
TOTAL OTHER INCOME
|
|
|
||||||
|
Net income
|
$
|
|
$
|
|
||||
|
Weighted average number of Class A ordinary shares subject to redemption outstanding, basic and diluted
|
|
|||||||
|
Basic and diluted net income per Class A ordinary share subject to redemption
|
$
|
|
$ | |||||
| Weighted average number of non-redeemable Class A ordinary shares outstanding, basic and diluted |
||||||||
| Basic and diluted net loss per non-redeemable Class A ordinary share |
$ | ( |
) | $ | ||||
|
Weighted average number of Class B ordinary shares outstanding, basic and diluted
|
|
|
||||||
|
Basic and diluted net income (loss) per Class B ordinary share
|
$
|
(
|
)
|
$ | ( |
) | ||
The accompanying notes are an
integral part of these unaudited condensed financial statements.
ENPHYS ACQUISITION CORP.
(UNAUDITED)
For the three months ended March 31, 2024
|
Class A
Ordinary Shares
|
Class B
Ordinary Shares
|
Additional
Paid In
|
Accumulated |
Shareholders’
|
||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares | Amount |
Capital
|
Deficit
|
Deficit
|
||||||||||||||||||||||
|
Balance, January 1, 2024
|
|
$
|
|
$ |
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||||||||
|
Accretion of Class A ordinary shares to redemption value
|
—
|
|
— |
|
(
|
)
|
(
|
)
|
||||||||||||||||||||
|
Net income
|
—
|
|
— |
|
|
|
||||||||||||||||||||||
|
Balance, March 31, 2024
|
|
$
|
|
$ |
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||||||||
For the three months ended March 31, 2023
|
Class A
Ordinary Shares
|
Class B
Ordinary Shares
|
Additional
Paid In
|
Accumulated
|
Shareholders’
|
||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares | Amount |
Capital
|
Deficit
|
Deficit
|
||||||||||||||||||||||
|
Balance, January 1, 2023
|
|
$ | $ |
$ |
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||||||||||
|
Accretion of Class A ordinary shares to redemption value
|
— |
— |
(
|
)
|
(
|
)
|
||||||||||||||||||||||
|
Net income
|
— |
— |
|
|
||||||||||||||||||||||||
|
Balance, March 31, 2023
|
|
$ | $ |
$ |
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
ENPHYS ACQUISITION CORP.
(UNAUDITED)
|
For the Three
Months Ended
|
||||||||
|
March 31,
2024
|
March 31,
2023
|
|||||||
|
Cash Flows From Operating Activities:
|
||||||||
|
Net income
|
$
|
|
$
|
|
||||
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
|
||||||||
|
Realized gains on investment held in Trust Account
|
|
(
|
)
|
|||||
|
Change in fair value of derivative warrant liabilities
|
|
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Prepaid expenses
|
(
|
)
|
(
|
)
|
||||
|
Other current assets
|
( |
) | ||||||
|
Accounts payable and accrued expenses
|
|
(
|
)
|
|||||
|
Net Cash Provided By (Used In) Operating Activities
|
|
(
|
)
|
|||||
| Cash Flows From Investing Activities: |
||||||||
|
Proceeds from redemption of securities held in Trust Account
|
||||||||
| Purchase of securities held in Trust Account |
( |
) | ||||||
| Net Cash Provided by Investing Activities |
||||||||
|
Cash Flows From Financing Activities:
|
||||||||
|
Proceeds from Sponsor extension note
|
|
|
||||||
| Advance from Sponsor | ||||||||
|
Proceeds from related party notes
|
|
|||||||
| Redemption of Class A ordinary shares |
( |
) | ||||||
|
Net Cash Used in Financing Activities
|
(
|
)
|
|
|||||
|
Net change in cash and cash held in Trust Account
|
(
|
)
|
(
|
)
|
||||
|
Cash and cash held in Trust at beginning of period(1)
|
|
|
||||||
|
Cash and cash held in Trust at end of period(2)
|
$
|
|
$
|
|
||||
|
Supplemental disclosure of non-cash financing activities:
|
||||||||
|
Accretion of Class A ordinary shares to redemption value
|
$
|
|
$
|
|
||||
| (1) |
|
| (2) |
|
The accompanying notes are an integral part of these unaudited condensed financial statements.
ENPHYS ACQUISITION CORP.
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND GOING CONCERN
Enphys Acquisition Corp. (the “Company”) was incorporated in the Cayman Islands on March 3, 2021. The Company was formed
for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is not limited to a
particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging
growth companies.
As of March 31, 2024, the Company had not commenced any operations. All activity for the period from March 3, 2021
(inception) through March 31, 2024 relates to the Company’s formation and the initial public offering (“Initial Public Offering”), which is described below. The Company will not generate any operating revenues until after the completion of its
initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the cash raised in the Initial Public Offering and held in the Trust.
On October 6, 2023, the Company held an extraordinary general meeting of shareholders (the “Extraordinary General Meeting”)
to vote on certain proposals as described below. At the Extraordinary General Meeting, the Company’s shareholders approved an amendment to the Company’s amended and restated memorandum and articles of association (the “Extension Amendment”) to
extend the date by which the Company must consummate a business combination from October 8, 2023 to February 8, 2024 (the “Extended Date”).
On October 17, 2023 and October 23, 2023, holders of 6,812,500 Class B ordinary shares of the Company voluntarily elected to convert such shares of Class B Common Stock to shares of Class A ordinary shares on a one -for-one basis in accordance with the Company’s amended and restated memorandum and articles of association.
Additionally, the Company’s public stockholders elected to redeem 24,301,795 shares of Class A Common Stock at a redemption price of approximately $10.53
per share, for an aggregate redemption amount of approximately $256 million.
On February 2, 2024, the Company held an extraordinary general meeting of the shareholder’s (the “Second Extraordinary
General Meeting”) to vote on certain proposals as described below. At the Second Extraordinary General Meeting, the Company’s shareholders approved an amendment to the Company’s amended and restated memorandum and articles of association (the
“Second Extension Amendment”) to extend the date by which the Company must consummate a business combination from February 8, 2024 to June 8, 2024 (the “Second Extended Date”).
Additionally, the Company’s shareholders elected to redeem 3,940,414 public shares of the Company at a redemption price of approximately $10.73
per share, for an aggregate redemption amount of approximately $42.3 million (the “Second Redemption”). After the satisfaction of the
Second Redemption on February 2, 2024, the balance in the Trust Account was approximately $67.2 million. As of March 31, 2024, the
balance in the Trust Account was approximately $67.8 million.
Initial Financing and Sponsor
The registration statement for the Company’s Initial Public Offering was declared effective on October 5, 2021. On October
8, 2021, the Company consummated the Initial Public Offering of 30.0 million units (“Units” and, with respect to the ordinary shares
included in the Units being offered, the “Public Shares”), generating gross proceeds of $300,000,000 , which is described in Note 3.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale (the “Private
Placement”) of an aggregate of 8.0 million warrants (the “Private Placement Warrants”) to Enphys Acquisition Sponsor LLC (the
“Sponsor”) at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company in the amount of $8.0 million.
On October 8, 2021, the underwriters purchased an additional 4.5 million Units pursuant to the exercise of the over-allotment option. The Units were sold at an offering price of $10.00 per Unit, generating additional gross proceeds to the Company of $45,000,000 .
Also, in connection with the partial exercise of the over-allotment option, the Sponsor purchased an additional 900,000 Private
Placement Warrants at a purchase price of $1.00 per warrant.
Trust Account
Following the closing of the Initial Public Offering and the exercise of the overallotment option on October 8, 2021, an
amount of $345.0 million ($10.00
per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and $6.9 million from the Private Placement
Warrants were placed in a trust account (“Trust Account”) which may be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”),
with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company,
until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the Trust Account, as described below. On October 10, 2023, to mitigate the risk of us being deemed to be an unregistered investment company
(including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act) and thus subject to regulation under the Investment Company Act, we instructed Continental, the trustee with respect to the trust account, to liquidate
the U.S. government treasury obligations or money market funds held in the trust account and thereafter to hold all funds in the trust account in an interest-bearing demand deposit account currently yielding interest of approximately 4.5 % per annum until the earlier of the consummation of our initial business combination or liquidation.
Initial Business Combination
The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial
Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to
complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more
operating businesses or assets with a fair market value equal to at least 80 % of the net assets held in the Trust Account (as
defined below) (excluding the deferred underwriting fees and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50 % or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it
not to be required to register as an investment company under the Investment Company Act.
The Company will provide the holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to
redeem all or a portion of their Public Shares either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to
whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then
in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest then in the Trust Account, net
of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. The Public Shares subject to redemption are recorded as temporary equity upon the completion of the
Initial Public Offering and subsequently accreted to redemption value in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing
Liabilities from Equity.
The Company will not redeem Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 (so that it does not then become subject to the U.S. Securities and Exchange Commission’s (“SEC”) “penny stock” rules) or any greater net
tangible asset or cash requirement which may be contained in the agreement relating to the Business Combination. If the Company seeks shareholder approval of the Business Combination, the Company will proceed with a Business Combination if a
majority of the outstanding shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a shareholder vote is not required by applicable law or stock exchange listing
requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the “Certificate of Incorporation”), conduct the
redemptions pursuant to the tender offer rules of the SEC and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock
exchange listing requirements, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to
the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Class B ordinary shares previously issued in March 2021 (including Class B ordinary shares converted
to Class A ordinary shares) (the “Founder Shares”) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public
Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.
Notwithstanding the foregoing, if the Company seeks shareholder approval of a Business Combination and it does not conduct
redemptions pursuant to the tender offer rules, the Certificate of Incorporation will provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a
“group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15 % of the Public Shares, without the prior consent of the Company.
The Sponsor has agreed (a) to waive its redemption rights with respect to the Founder Shares and Public Shares held by it
in connection with the completion of a Business Combination and (b) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemptions in connection with a
Business Combination or to redeem 100 % of its Public Shares if the Company does not complete a Business Combination within the
Combination Period (as defined below) or (ii) with respect to any other provision relating to shares’ rights or pre-business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public
Shares in conjunction with any such amendment.
If the Company has not completed a Business Combination within 32 months from the closing of the Initial Public Offering (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii)
as promptly as reasonably possible but not more than business days thereafter, redeem the Public Shares, at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Shareholders’
rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the
Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or
liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.
The holders of the Founders Shares have agreed to waive their liquidation rights with respect to the Founder Shares if the
Company fails to complete a Business Combination within the Combination Period. However, if the holders of Founder Shares acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating
distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting fees held in the Trust Account in the
event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the
Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00 ).
In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the
extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust
Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of
the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, in
each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the
Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is
deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust
Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company’s independent registered accounting firm), prospective target businesses and other entities with which the Company does business,
execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.
Going Concern, Liquidity and Management’s Plan
As of March 31, 2024, the Company had $159,158 in cash and working capital deficit of $1,443,573 . As of December
31, 2023, the Company had $112,495 in cash and working capital deficit of $960,968 .
In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Combination Period is less than one year from the date of the issuance of the financial
statements. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period and the Company does not have sufficient cash and working capital to sustain its operation. As a
result, these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The financial statements do not include any adjustments that
might result from the outcome of the uncertainty.
Risks and Uncertainties
Management continues to evaluate the impact of global conflicts and any further escalation of hostilities related thereto, terrorist
attacks, natural disasters or a significant outbreak of other infectious diseases, on the industry and has concluded that while it is reasonably possible that such events could have a negative effect on the Company’s financial position,
results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the
outcome of these uncertainties.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (“U.S. GAAP”) for interim financial information and Article 8 of Regulation S-X. The accompanying unaudited condensed
financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K filed by the Company with the SEC on April 16, 2024. In the opinion of the Company’s management,
these condensed financial statements include all adjustments, which are only of a normal and recurring nature, necessary for a fair statement of the Company’s financial position as of March 31, 2024 and the Company’s results of operations and cash
flows for the periods presented. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year ending December 31, 2024.
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the
“Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is
irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth
company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly,
the actual results could differ significantly from those estimates.
Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did no t have any cash equivalents as of March 31, 2024 and December 31, 2023.
Cash held in Trust Account
At March 31, 2024 and December 31, 2023, all of the assets held in the Trust Account were in an interest bearing demand deposit account. Gains and losses resulting
from the change in fair value of these securities are recorded to net income each period. At March 31, 2024 and December 31, 2023, the cash held in the Trust Account totaled $67,789,263 and $108,901,049 , respectively.
Class A Ordinary Shares subject to Possible Redemption
The Company’s Class A ordinary shares subject to possible redemption contain certain redemption rights that are considered by the Company to be outside of the Company’s
control and subject to the occurrence of uncertain future events. Accordingly, as of March 31, 2024 and December 31, 2023, the Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’
deficit section of the Company’s balance sheets.
The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the
end of each reporting period. Such changes are reflected in additional paid-in-capital, or in the absence of additional capital, in accumulated deficit, in the statements of changes in shareholders’ deficit.
At March 31, 2024 and December 31, 2023, the Class A ordinary shares reflected in the balance sheets is reconciled in the following table:
|
Number of
Shares
|
Amount |
|||||||
|
Balance, December 31, 2022
|
|
$
|
|
|||||
|
Redemption of
|
(
|
)
|
(
|
)
|
||||
|
Remeasurement adjustment of carrying value to redemption value
|
-
|
|
||||||
|
Balance, December 31, 2023
|
|
$
|
|
|||||
|
Redemption of
|
(
|
)
|
(
|
)
|
||||
|
Remeasurement adjustment of carrying value to redemption value
|
-
|
|
||||||
|
Balance, March 31, 2024
|
|
$
|
|
|||||
Income Taxes
The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their
respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement
of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and
penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2024 and 2023. The Company is currently not aware of any issues under review that
could result in significant payments, accruals or material deviation from its position.
There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not
levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements.
Net Income per Share
Net income per share is computed by dividing net income by the weighted average number of ordinary shares outstanding during the period. The Company
applies the two-class method in calculating earnings and losses per share. Earnings and losses are shared pro rata between the two classes of shares. The calculation of diluted income per ordinary share does not consider the effect of the warrants
issued in connection with the (i) Public Offering and (ii) Private Placement, since their inclusion would be anti-dilutive under the two-class method. As a result, diluted earnings and losses per ordinary share is the same as basic earnings and
losses per ordinary share for the periods presented. The warrants are exercisable to purchase 26,150,000 Class A ordinary shares in the
aggregate.
The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts) for the three months ended March 31,
2024:
|
For the Three Months Ended
March 31, 2024 |
||||
|
Net income
|
$
|
|
||
|
Accretion of temporary equity to redemption value
|
(
|
)
|
||
|
Net loss including accretion of temporary equity to redemption value
|
$
|
(
|
)
|
|
|
For the Three Months Ended
March 31, 2024
|
||||||||||||
|
|
Class A
Redeemable
|
Class A
Non-Redeemable
|
Class B
Non-Redeemable
|
|||||||||
|
Basic and diluted net income per share:
|
||||||||||||
|
Numerator:
|
||||||||||||
|
Allocation of net loss including accretion of temporary equity
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Allocation of accretion of temporary equity to Class A Ordinary shares
|
|
|
|
|||||||||
|
Allocation of net income (loss)
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
|
Denominator:
|
||||||||||||
|
Weighted-average shares outstanding
|
|
|
|
|||||||||
|
Basic and diluted net income (loss) per ordinary share
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share
amounts) for the three months ended March 31, 2023:
|
For the Three Months Ended
March 31, 2023
|
||||
|
Net income
|
$
|
|
||
|
Accretion of temporary equity to redemption value
|
(
|
)
|
||
|
Net loss including accretion of temporary equity to redemption value
|
$
|
(
|
)
|
|
|
|
For the Three Months Ended
March 31, 2023
|
|||||||
|
|
Redeemable
|
Non-Redeemable
|
||||||
|
Basic and diluted net loss per share:
|
||||||||
|
Numerator:
|
||||||||
|
Allocation of net loss including accretion of temporary equity
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
Allocation of accretion of temporary equity to Class A Ordinary shares
|
|
|
||||||
|
Allocation of net income (loss)
|
$
|
|
$
|
(
|
)
|
|||
|
Denominator:
|
||||||||
|
Weighted-average shares outstanding
|
|
|
||||||
|
Basic and diluted net income (loss) per ordinary share
|
$
|
|
$
|
(
|
)
|
|||
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a
financial institution, which, at times, may exceed federally insured limits. As of March 31, 2024 and December 31, 2023, the Company has not experienced losses on this account. The Company places its cash with major banks and monitors the credit
ratings of such banks. The concentration of cash in our Trust Account as of March 31, 2024 exposes the Company to increased credit risk with such banks.
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an
orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted
quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
|
●
|
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical
instruments in active markets;
|
|
●
|
Level 2, defined as inputs other than quoted prices in active markets that are either
directly or indirectly observable such as quoted prices or similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
|
|
●
|
Level 3, defined as unobservable inputs in which little or no market data exists,
therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
|
The fair value of the Company’s financial assets and liabilities, except for derivative warrant liabilities, approximates the carrying amounts represented in the balance
sheets, primarily due to their short-term nature (see Note 8).
Derivative Warrant Liabilities
The Company accounts for the Public Warrants and the Private Placement Warrants issued in connection with the Initial Public Offering and the Private Placement in
accordance with the guidance contained in ASC 815, “Derivatives and Hedging” whereby under that provision the Public Warrants and the Private Placement Warrants do not meet the criteria for equity treatment
and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at fair value and adjusts the balance to fair value at each reporting date. This liability is re-measured at each balance sheet date
until the Public Warrants and the Private Placement Warrants are exercised or expire, and any change in fair value will be recognized in the Company’s statements of operations. Such warrant classification is also subject to re-evaluation at each
reporting period.
Recent Accounting Standards
Management does not believe that any
recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.
NOTE 3 - PRIVATE PLACEMENT
Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale (the “Private
Placement”) of an aggregate of 8,000,000 warrants (the “Private Placement Warrants”) to Enphys Acquisition Sponsor LLC (the “Sponsor”)
at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company in the amount of $8,000,000 .
In connection with the exercise of the over-allotment option, the Sponsor purchased an additional 900,000 Private Placement Warrants at a purchase price of $1.00 per warrant.
A portion of the proceeds from the Private Placement Units was added to the proceeds from the Initial Public Offering held in
the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares
(subject to the requirements of applicable law) and the Private Placement Units will be worthless.
The Private Placement Warrants (including the Class A ordinary shares issuable upon exercise of the Private Placement
Warrants) will not be transferable, assignable or salable until 30 days after the completion of an Initial Business Combination,
subject to certain exceptions.
NOTE 4 - RELATED PARTIES
Founder Shares
During the period ended March 4, 2021, the Sponsor received 7,187,500 of the Company’s Class B ordinary shares (the “Founder Shares”) for an aggregate price of $25,000 in exchange for paying certain expenses on behalf of the Company. On October 5, 2021, the Company effected a share capitalization issuing 0.2 of a share for each ordinary share in issue, resulting in the Sponsor holding an aggregate of 8,625,000 Founder Shares. The Founder Shares included an aggregate of up to 1,125,000
shares subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full or in part, so that the number of Founder Shares would equal, on an as-converted basis, approximately 20 % of the Company’s issued and outstanding ordinary shares after the Initial Public Offering. Upon exercise of the underwriter’s overallotment
option, these shares are no longer subject to forfeiture. Concurrent with the offering, the Sponsor transferred 20,000 Founder
Shares to each of the Company’s independent directors as consideration for services already performed on behalf of the Company. These 80,000
Founder Shares were not subject to forfeiture in the event that the underwriter’s did not exercise the over-allotment option. Upon transfer of these shares, the Company recorded $557,600 of share-based compensation for services provided by the independent directors in 2021.
Upon close of the Initial Public Offering, the anchor investors received 2,050,200 Founder Shares (“Anchor Shares”) with the Company cancelling an equivalent number of shares. The grant date fair value of the shares transferred was $6.97 per share or an aggregate of $14,289,894
which was treated as an offering cost in accordance with Staff Accounting Bulletin 5A. Accordingly, the offering cost was allocated to the separable financial instruments issued in the Initial Public Offering in the same proportion that the
proceeds were allocated to such instruments.
The initial shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder
Shares until the earlier to occur of: (A) one year after the completion of a Business Combination and (B) subsequent to a Business
Combination, (x) if the last reported sale price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for
stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 -trading day period commencing at least 150
days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their shares
of ordinary shares for cash, securities or other property.
On October 17, 2023 and October 23, 2023, in connection with the Extension Amendment, 6,812,500 Founder Shares were converted into Class A ordinary shares (see Note 1).
General and Administrative Services
Commencing
on the date the Units were first listed on the NYSE, the Company agreed to pay the Sponsor a total of $10,000 per month for office
space, utilities and secretarial and administrative support. Upon completion of the Initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. During the three months ended March 31, 2024 and 2023, the Company recorded $30,000 respectively in fees pursuant to the agreement, which are recorded in the statements of operations. As of March 31, 2024 and December 31, 2023, $300,000 and $270,000 , respectively, was due to the Sponsor which is included in accounts payable and accrued expenses on the accompanying balance sheets.
Extension Notes
On October 10, 2023, the Company issued a promissory
note (the “First Extension Note”) to the Sponsor or its registered assigns or successors in interest (the “Payee”), pursuant to which the Payee agreed that the Payee or one or more of its affiliates or designees will deposit into the
Company’s trust account established in connection with its initial public offering an amount equal to the lesser of (i) $0.025 per Class A ordinary
share of the Company multiplied by the number of Class A ordinary shares of the Company then outstanding and (ii) $100,000 , for each calendar month
(each, a “Deposit”) until the earlier of (i) the Company’s completion of a business combination and (ii) February 8, 2024 (the “Extended Date”). The maximum aggregate amount of deposits shall be $400,000 .
The extension note is non-interest bearing and payable promptly on the date on which the Company consummates the Business Combination. As of March 31, 2024, a total of $400,000
was deposited into the Trust Account pursuant to this agreement.
On February 6, 2024, the Company issued a promissory note (the “Second Extension Note”) to Enphys Management Company LLC, pursuant to which Enphys Management Company LLC agreed that it or one or more of its affiliates or designees will
deposit into the Company’s Trust Account an amount equal to the lesser of (i) $0.02 per public share of the Company multiplied by
the number of public shares of the Company then outstanding and (ii) $80,000 , for each calendar month (each, a “Deposit”) until the
earlier of (i) the Company’s completion of a business combination and (ii) June 8, 2024. The maximum aggregate amount of deposits shall be $320,000 .
The Second Extension Note is non-interest bearing and payable promptly on the date on which the Company consummates the Business Combination. As of March 31, 2024, a total of $160,000 was deposited into the Trust Account pursuant to this agreement.
As of March 31, 2024 and December 31, 2023, there was a
total of $560,000 and $300,000
outstanding on the extension notes, respectively.
Notes Payable – Related Parties
On October 30, 2023, the Company issued a promissory note to the Sponsor, as amended by the First Amendment to Promissory note dated March 1, 2024, pursuant to which the Company may borrow an aggregate of $300,000 from the Sponsor in order to fund costs and expenses related to the Company’s daily operations and due diligence in connection with a
potential business combination and which the Company shall repay on the date on which the Company consummates an initial business combination (the “OPEX Note”). If the Company has not consummated an initial business combination on or prior to
December 31, 2024, then the Sponsor shall have no recourse against the Company and all outstanding amounts of principal and accrued and unpaid interest payable under the Promissory Note shall immediately terminate and all related indebtedness
shall be deemed cancelled. Interest on the notes shall accrue on the principal of each drawdown under the note outstanding from time to time at a rate per annum equal to Term SOFR for the interest period therefor plus 3 %. As of December 31, 2023, there was $300,000
outstanding pursuant to this note.
On March 1, 2024, the Company issued a promissory note to the Sponsor (the “2024 Variable Rate Promissory Note”), pursuant to which the Company may borrow up to an aggregate of $100,000 . The 2024 Variable Rate Promissory Note subject to a variable interest rate equal to Term SOFR for the interest period therefor plus 300 basis points (3 %) and payable on the date on which the Company consummates the Business Combination. If the Company has not consummated a Business Combination
on or prior to December 31, 2024, then the Sponsor shall have no recourse against the Company and all outstanding amounts of principal and accrued and unpaid interest payable under the 2024 Variable Rate Promissory Note shall immediately
terminate and all related indebtedness shall be deemed cancelled. As of March 31, 2024 there was $100,000 outstanding under the
2024 Variable Rate Promissory Note.
On March 1, 2024, the Company issued a promissory note to the Sponsor (the “2024 Fixed Rate Promissory Note”), pursuant to which the Company may borrow up to an aggregate of $100,000 . The 2024 Fixed Rate Promissory Note subject to a fixed interest rate equal to twelve percent (12 %) per annum and payable on the date on which the Company consummates the Business Combination. If the Company has not consummated a Business Combination on or prior
to December 31, 2024, then the Sponsor shall have no recourse against the Company and all outstanding amounts of principal and accrued and unpaid interest payable under the 2024 Fixed Rate Promissory Note shall immediately terminate and all
related indebtedness shall be deemed cancelled. As of March 31, 2024, there was $100,000 outstanding under the 2024 Fixed Rate
Promissory Note.
As of March 31, 2024 and December 31, 2023, there was $32,023 and $24,969 of interest on the above notes
outstanding, which is included in accounts payable and accrued expenses on the accompanying balance sheets.
Related Party Loans
In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor,
or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon
completion of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of the notes may be converted
upon completion of a Business Combination into warrants at a price of $1.00 per warrant. Such warrants would be identical to the
Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be
used to repay the Working Capital Loans. As of March 31, 2024 and December 31, 2023, there were no amounts outstanding under the
Working Capital Loans.
NOTE 5 - COMMITMENTS AND CONTINGENCIES
Registration Rights
The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working
Capital Loans (and any shares of ordinary shares issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) will be entitled to
registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder Shares, only
after conversion to shares of Class A ordinary shares). The holders of these securities will be entitled to make up to three demands,
excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business
Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any
registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such
registration statements.
Underwriting Agreement
The Company granted the underwriters a 45-day option from the date of the Initial Public Offering to purchase up to 4,500,000
additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting fees.
The underwriters were entitled to a cash underwriting fee of $0.20 per Unit, or $6,000,000 in the aggregate (or $6,900,000 in the aggregate if the underwriters’ over-allotment option is exercised in full), payable upon the closing of the Initial Public Offering.
In addition, the underwriters were entitled to a deferred fee of $0.35 per Unit, or $10,500,000 in the aggregate (or $12,075,000 in the aggregate if
the underwriters’ over-allotment option is exercised in full).
On October 8, 2021, the underwriters purchased an additional 4,500,000 Units pursuant to the exercise of the over-allotment option. The Units were sold at an offering price of $10.00 per Unit, generating additional gross proceeds to the Company of $45,000,000 .
The deferred underwriting fee of $12,075,000 will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes the Business Combination, subject to the terms of the underwriting
agreement.
NOTE 6 - SHAREHOLDER’S EQUITY
Preferred Shares - The Company is authorized to issue 1,000,000 shares of preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of March 31, 2024 and
December 31, 2023, there were no preference shares issued or outstanding.
Class A Ordinary Shares - The Company is authorized to issue 300,000,000 shares of Class A ordinary shares with a par value of $0.0001 per share. Holders of Class A ordinary shares are entitled to one
vote for each share. As of March 31, 2024 and December 31, 2023, there were 13,070,291 and 17,010,705 shares of the Class A ordinary shares issued and outstanding, including 6,257,791 and 10,198,205 Class A ordinary shares subject to possible
conversion that are classified as temporary equity in the accompanying balance sheets, respectively.
Class B Ordinary Shares - The Company is authorized to issue 30,000,000 shares of Class B ordinary shares with a par value of $0.0001 per share. Holders of Class B ordinary shares are entitled to one
vote for each share. As of March 31, 2024 and December 31, 2023, there were 1,812,500 shares of Class B ordinary shares issued and outstanding. Upon close of the Initial Public Offering, the Class B ordinary shares were allocated as follows: 6,494,800 by Sponsor, 80,000
by independent directors and 2,050,200 by anchor investors.
Only holders of the Class B ordinary shares will have the right to vote on the election of directors prior to the Business
Combination. Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial
Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in
effect upon completion of the offering.
The shares of Class B ordinary shares will automatically convert into Class A ordinary shares at the time of a Business
Combination, or earlier at the option of the holder, on a one -for-one basis, subject to adjustment. In the case that additional shares
of Class A ordinary shares, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B
ordinary shares shall convert into shares of Class A ordinary shares will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B ordinary shares agree to waive such adjustment with respect to any such issuance or
deemed issuance) so that the number of shares of Class A ordinary shares issuable upon conversion of all shares of Class B ordinary shares will equal, in the aggregate, on an as-converted basis, 20 % of the sum of the total number of all shares of ordinary shares outstanding upon the completion of Initial Public Offering plus all shares of Class A ordinary shares and
equity-linked securities issued or deemed issued in connection with a Business Combination (net of the number of shares of Class A ordinary shares redeemed in connection with a Business Combination), excluding any Class A ordinary shares or
equity-linked securities issued or issuable to any seller of an interest in the target to us in a Business Combination and any Private Placement Warrants issued to the Sponsor.
NOTE 7 - DERIVATIVE WARRANT LIABILITIES
The Company accounts for the 26,150,000
warrants issued in connection with the Initial Public Offering (representing 17,250,000 Public Warrants and 8,900,000 Private Placement Warrants) in accordance with the guidance contained in ASC 815-40, “Derivatives and
Hedging”. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company classifies each warrant as a derivative warrant
liability at its fair value.
Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of
the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the
completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will
expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.
The Company will not be obligated to deliver any shares of Class A ordinary share pursuant to the exercise of a warrant and
will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A ordinary shares issuable upon exercise of the warrants is then effective and a current
prospectus relating to those shares of Class A ordinary shares is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for
cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the
state of residence of the exercising holder, or an exemption from registration is available.
The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A
ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A ordinary shares until the warrants expire or are redeemed. Notwithstanding the above, if the Class A ordinary share is
at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of
Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a
registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.
Redemption of Warrants When the Price per Share of Class A Ordinary
Share Equals or Exceeds $18.00 - Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants:
| • |
in whole and not in part;
|
| • |
at a price of $
|
| • |
upon a minimum of
|
| • |
if, and only if, the last reported sale price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganization,
recapitalizations and the like) for any
|
If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable
to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of Warrants When the Price per Share of Class A Ordinary
Share Equals or Exceeds $10.00 - Once the warrants become exercisable, the Company may redeem the outstanding Public warrants:
| • |
in whole and not in part;
|
| • |
at a price of $
|
| • |
upon a minimum of
|
| • |
if, and only if, the last reported sale price of the Class A ordinary share equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganization,
recapitalizations and the like) for any
|
| • |
if, and only if, the private placement warrants are also concurrently exchanged at the same price (equal to a number of shares of Class A ordinary share) as the outstanding public
warrants, as described above.
|
If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require
any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the Public Warrants may be adjusted in
certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of
ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the
Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the
Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless.
The Private Placement Warrants will be identical to the Public Warrants underlying the Units being sold in the Initial Public
Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or saleable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless
basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted
transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
NOTE 8 - FAIR VALUE MEASUREMENTS
The following table presents information about the Company’s assets and liabilities that are measured at fair value at March
31, 2024 and December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
|
Description
|
Level
|
March 31,
2024 |
December 31,
2023
|
|||||||||
|
Liabilities:
|
||||||||||||
|
Derivative warrant liabilities – Private Placement Warrants
|
2
|
$
|
|
$
|
|
|||||||
|
Derivative warrant liabilities – Public Warrants
|
1
|
$ |
|
$ |
|
|||||||
|
$
|
|
$
|
|
|||||||||
The Warrants are measured at
fair value on a recurring basis.
The following table provides a summary of the changes in the fair value of the Company’s financial instruments that are
measured at fair value on a recurring basis:
|
Private
Placement
Warrants
|
Public
Warrants
|
Total
|
||||||||||
|
Fair value at December 31, 2023
|
$
|
|
$
|
|
$
|
|
||||||
|
Change in fair value
|
|
|
|
|||||||||
|
Fair value at March 31, 2024
|
$
|
|
$
|
|
$
|
|
||||||
|
Private
Placement
Warrants
|
Public
Warrants
|
Total
|
||||||||||
|
Fair value at December 31, 2022
|
$
|
|
$
|
|
$
|
|
||||||
|
Change in fair value
|
|
|
|
|||||||||
|
Fair value at March 31,
2023
|
$
|
|
$
|
|
$
|
|
||||||
| Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
References to “we,” “us,” “company” or “our company” are to Enphys Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of
operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes
forward-looking statements that involve risks and uncertainties.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and
Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward- looking statements on our current expectations and projections about future events. These forward-looking statements are subject to
known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements
expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or
the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other U.S. Securities and Exchange Commission (“SEC”) filings.
Overview
We are a blank check company incorporated on March 3, 2021, as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). We are an emerging growth company and, as such, we are subject to all of the risks associated with emerging growth
companies.
Our Sponsor is Enphys Acquisition Sponsor LLC, a Delaware limited liability company.
On August 18, 2023, we signed a non-binding letter of intent for a business combination with a leading and well-established advanced biofuels company in Latin America (the
“Target”). We continue to pursue a business combination with the Target. However, no assurances can be made that we will enter into a definitive agreement regarding a business combination with the Target. Any transaction would be subject to board
and equityholder approval of both the company and the Target, regulatory approvals and other customary closing conditions.
On October 6, 2023, at its First Extraordinary General Meeting, the Company’s shareholders approved the First Extension Amendment to the Company’s amended and restated memorandum
and articles of association to extend the date by which the Company must consummate a business combination from October 8, 2023 to February 8, 2024.
On February 2, 2024, at its Second Extraordinary General Meeting, the Company’s shareholders approved the Second Extension Amendment to the Company’s amended and restated
memorandum and articles of association to extend the date by which the Company must consummate a business combination from February 8, 2024 to June 8, 2024.
If we have not completed a Business Combination by June 8, 2024, (the “Combination Period”), we will (i) cease all operations except for the purpose of winding up; (ii) as
promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the
funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which
redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the
approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law.
Liquidity and Capital Resources
As of March 31, 2024, the Company had $159,158 in cash and a working capital deficit of $1,443,573. We intend to use the funds held outside the Trust Account primarily to identify
and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate
documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination.
In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors
may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without
interest, or, at the lender’s discretion, up to $1.5 million of the notes may be converted upon completion of a Business Combination into warrants at a price of $1.00 per warrant. Such warrants would be identical to the Private Placement
Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the
Working Capital Loans.
On March 4, 2021, the Company issued an unsecured promissory note to the Sponsor (the “2021 Promissory Note”), pursuant to which the Company may borrow up to an aggregate
principal amount of $300,000. The 2021 Promissory Note is non-interest bearing and payable on the earlier of (i) December 31, 2021, or (ii) the consummation of the Initial Public Offering. As of March 31, 2024 and December 31, 2023, there was no
amount outstanding under the 2021 Promissory Note.
On October 30, 2023, the Company issued a promissory note to the Sponsor (the “2023 Promissory Note”), as amended by the First Amendment to Promissory note dated March 1, 2024,
pursuant to which the Company may borrow up to an aggregate of $300,000. The 2023 Promissory Note subject to a variable interest rate equal to Term SOFR for the interest period therefor plus 300 basis points (3%) and payable on the date on which
the Company consummates the Business Combination. If the Company has not consummated a Business Combination on or prior to December 31, 2024, then the Sponsor shall have no recourse against the Company and all outstanding amounts of principal
and accrued and unpaid interest payable under the 2023 Promissory Note shall immediately terminate and all related indebtedness shall be deemed cancelled. As of March 31, 2024 and December 31, 2023, there was $300,000 outstanding under the 2023
Promissory Note.
On March 1, 2024, the Company issued a promissory note to the Sponsor (the “2024 Variable Rate Promissory Note”), pursuant to which the Company may borrow up to an aggregate of
$100,000. The 2024 Variable Rate Promissory Note subject to a variable interest rate equal to Term SOFR for the interest period therefor plus 300 basis points (3%) and payable on the date on which the Company consummates the Business
Combination. If the Company has not consummated a Business Combination on or prior to December 31, 2024, then the Sponsor shall have no recourse against the Company and all outstanding amounts of principal and accrued and unpaid interest payable
under the 2024 Variable Rate Promissory Note shall immediately terminate and all related indebtedness shall be deemed cancelled. As of March 31, 2024 there was $100,000 outstanding under the 2024 Variable Rate Promissory Note.
On March 1, 2024, the Company issued a promissory note to the Sponsor (the “2024 Fixed Rate Promissory Note”), pursuant to which the Company may borrow up to an aggregate of
$100,000. The 2024 Fixed Rate Promissory Note subject to a fixed interest rate equal to twelve percent (12%) per annum and payable on the date on which the Company consummates the Business Combination. If the Company has not consummated a
Business Combination on or prior to December 31, 2024, then the Sponsor shall have no recourse against the Company and all outstanding amounts of principal and accrued and unpaid interest payable under the 2024 Fixed Rate Promissory Note shall
immediately terminate and all related indebtedness shall be deemed cancelled. As of March 31, 2024, there was $100,000 outstanding under the 2024 Fixed Rate Promissory Note.
Our registration statement for our initial public offering (the “Initial Public Offering”) became effective on October 5, 2021. On October 8, 2021, we consummated the Initial
Public Offering of 34.5 million units (the “Units” and, with respect to the Class A ordinary shares included in the Units, the “Public Shares”), including 4.5 million additional Units to cover over-allotments (the “Over-Allotment Units”), at
$10.00 per Unit, generating gross proceeds of $345 million, and incurring offering costs of $19,707,238 (including deferred underwriting fees of $12,075,000).
Simultaneously with the closing of the Initial Public Offering, we consummated the private placement (“Private Placement”) of 8.9 million warrants (each, a “Private Placement
Warrant” and collectively, the “Private Placement Warrants”), at a price of $1.00 per Private Placement Warrant with the Sponsor, generating gross proceeds of $8.9 million.
Upon the closing of the Initial Public Offering and the Private Placement, $345 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and
certain of the proceeds of the Private Placement were placed in a trust account (the “Trust Account”), located in the United States with Continental Stock Transfer & Trust Company acting as trustee, and invested only in U.S. “government
securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest
only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. On October 10, 2023, to mitigate the risk of us being deemed to be an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act) and thus subject to regulation under the
Investment Company Act, we instructed Continental, the trustee with respect to the trust account, to liquidate the U.S. government treasury obligations or money market funds held in the trust account and thereafter to hold all funds in the
trust account in an interest-bearing demand deposit account currently yielding interest of approximately 4.5% per annum until the earlier of the consummation of our initial business combination or liquidation.
At March 31, 2024 and December 31, 2023, we had approximately $67.8 million and $108.9 million in the Trust Account. The amount is the Trust Account is intended to be applied
generally toward consummating a Business Combination.
In connection with the shareholders’ vote at the First Extraordinary General Meeting on October 6, 2023, the holders of
24,301,795 public shares of the Company properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.53 per share, for an aggregate redemption amount of approximately $256 million. After the satisfaction of the First Redemption, the balance in the trust account was approximately $107 million.
On October 10, 2023, the Company issued a promissory note (the “First Extension Note”) to the Sponsor, pursuant to which the Sponsor agreed that the Sponsor or one or more of its
affiliates or designees will deposit into the Company’s Trust Account an amount equal to the lesser of (i) $0.025 per public share of the Company multiplied by the number of public shares of the Company then outstanding and (ii) $100,000, for
each calendar month (each, a “Deposit”) until the earlier of (i) the Company’s completion of a business combination and (ii) February 8, 2024. The First Extension Note is non-interest bearing and payable on the date on which the Company
consummates the Business Combination. As of March 31, 2024, there was $400,000 outstanding under the First Extension Note.
In connection with the shareholders’ vote at the Second Extraordinary General Meeting on February 2, 2024, the holders of 3,940,414 public shares of the Company properly exercised
their right to redeem their shares for cash at a redemption price of approximately $10.73 per share, for an aggregate redemption amount of approximately $42.3 million. After the satisfaction of the Second Redemption, the balance in the trust
account was approximately $67.2 million.
On February 6, 2024, the Company issued a promissory note (the “Second Extension Note”) to Enphys Management Company LLC, pursuant to which Enphys Management Company LLC agreed
that it or one or more of its affiliates or designees will deposit into the Company’s Trust Account an amount equal to the lesser of (i) $0.02 per public share of the Company multiplied by the number of public shares of the Company then
outstanding and (ii) $80,000, for each calendar month (each, a “Deposit”) until the earlier of (i) the Company’s completion of a business combination and (ii) June 8, 2024. The Second Extension Note is non-interest bearing and payable on the date
on which the Company consummates the Business Combination. As of March 31, 2024, there was $160,000 outstanding under the Second Extension Note.
As of March 31, 2024 and December 31, 2023, there was a total of $560,000 and $300,000 outstanding on the First and Second Extension notes, respectively.
In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures
of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Combination Period is less than one year from the date of the issuance of the financial statements. There is no assurance that
the Company’s plans to consummate a Business Combination will be successful within the Combination Period and the Company does not have sufficient cash and working capital to sustain its operation. As a result, these factors raise substantial
doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of the
uncertainty.
Results of Operations
Our entire activity from inception up to March 31, 2024, was in preparation for our formation and the preparation of our Initial Public Offering. We will not be generating any
operating revenues until the closing and completion of our initial Business Combination, at the earliest.
For the three months ended March 31, 2024, we had net income of $547,537, which consisted of the related party administrative fee of $30,000, general and administrative expenses
of $185,551, interest expense of $7,054 and a loss of $156,900 for the change in derivative liabilities offset by interest earned on the Trust Account of $927,042.
For the three months ended March 31, 2023, we had net income of $2,801,083, which consisted of general and administrative expenses of $181,930 and $784,500 for the net change in
derivative warrant liabilities offset by the income earned on the investments in the Trust Account of $3,767,513.
Contractual Obligations
Registration Rights
The holders of Founder Shares, Private Placement Warrants, Class A ordinary shares underlying the Private Placement Warrants and warrants that may be issued upon conversion of
Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a
registration rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. These holders will be entitled to certain demand and “piggyback” registration
rights. We will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
We granted the underwriters a 45-day option from the final prospectus relating to the Initial Public Offering to purchase up to 4.5 million additional Units to cover
over-allotments, if any, at the Initial Public Offering price less the underwriting fees. On October 8, 2021, the underwriters fully exercised their over-allotment option.
The underwriters were entitled to an underwriting fee of $0.20 per Unit, or $7.0 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35
per unit, or approximately $12.0 million in the aggregate will be payable to the underwriters for deferred underwriting fees. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event
that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
Critical Accounting Estimates
The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. The Company did
not have any critical accounting estimates.
Recent Accounting Pronouncements
Our management does not believe that there are any recently issued, but not yet effective, accounting pronouncements, if currently adopted, that would have a material effect on
our financial statements. See Note 2 to the accompanying financial statements.
JOBS Act
The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public
companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the
adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the
financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set
forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial
reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement
that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose
certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years
following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.
Recent Developments
On May 16, 2024, the Company filed a definitive proxy statement to invite the shareholders of the Company to attend an Extraordinary General Meeting of the Company that is being
held to consider and vote upon a special resolution to amend the Company’s Amended and Restated Memorandum and Articles of Association, as amended by special resolutions adopted on October 6, 2023 and February 2, 2024, to extend the date by which
the Company must consummate a business combination from June 8, 2024 (the date which is 32 months from the closing date of the Company’s initial public offering) to December 8, 2024 (the date which is 38 months from the closing date of the
Company’s initial public offering).
| Item 3. |
Quantitative and Qualitative Disclosures About Market Risk
|
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
| Item 4. |
Controls and Procedures
|
Disclosure Controls and Procedures
Disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in its reports filed with the SEC under the Exchange Act
is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s principal executive
officer, principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Under the supervision and with the participation of the Company’s management, including the Company’s principal executive officer and principal financial officer, the
Company conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures as of March 31, 2024, as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act. Based on this
evaluation, the Company’s principal executive officer and principal financial officer have concluded that material weaknesses existed and the Company’s disclosure controls and procedures were not effective due to the material weaknesses that
are disclosed in Item 9A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 which continue to exist as of March 31, 2024..
The material weaknesses include: (1) the Company did not design and maintain effective internal controls over the valuation of the public warrants and private placement
warrants, and (2) presentation of the statements of cash flows.
Changes in Internal Control over Financial Reporting
During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under
the Exchange Act that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| Item 1. |
Legal Proceedings
|
None.
| Item 1A. |
Risk Factors.
|
A description of the risks associated with our business, financial condition, and results of operations is set forth in Part I, Item 1A, “Risk Factors” of our annual report on
Form 10-K filed with the SEC on April 16, 2024 (“Form 10-K”). Except as set forth below, as of the date of this Quarterly Report on Form 10-Q, there have been no material changes from the risk factors previously disclosed in our Form 10-K.
| Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds
|
None.
| Item 3. |
Defaults Upon Senior Securities
|
None.
| Item 4. |
Mine Safety Disclosures
|
Not applicable.
| Item 5. |
Other Information
|
| Item 6. |
Exhibits.
|
|
Exhibit
Number
|
Description
|
|
|
Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302
of the Sarbanes-Oxley Act of 2002.
|
||
|
Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302
of the Sarbanes-Oxley Act of 2002.
|
||
|
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.
|
||
|
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.
|
||
|
101.INS*
|
Inline XBRL Instance Document
|
|
|
101.SCH*
|
Inline XBRL Taxonomy Extension Schema Document
|
|
|
101.CAL*
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
|
| 101.DEF* |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
| 101.LAB* |
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
| 101.PRE* |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
104*
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
|
*
|
Filed herewith.
|
|
**
|
Furnished.
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
ENPHYS ACQUISITION CORP.
|
||
|
Date: May 17, 2024
|
By:
|
/s/ Pär Lindström
|
|
Name: Pär Lindström
|
||
|
Title: Chief Financial Officer
|
||
28